IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $605,918 | +5.3% | 13,358 | -4.7% | 0.00% | 0.0% |
| Q2 2023 | $575,240 | -0.2% | 14,020 | -13.0% | 0.00% | 0.0% |
| Q1 2023 | $576,201 | +2.9% | 16,122 | +8.8% | 0.00% | 0.0% |
| Q4 2022 | $559,752 | -21.9% | 14,820 | -8.5% | 0.00% | 0.0% |
| Q3 2022 | $717,000 | +11.9% | 16,198 | -6.5% | 0.00% | 0.0% |
| Q2 2022 | $641,000 | -19.4% | 17,323 | -19.3% | 0.00% | 0.0% |
| Q1 2022 | $795,000 | +36.6% | 21,458 | +12.3% | 0.00% | 0.0% |
| Q4 2021 | $582,000 | +5.8% | 19,115 | +16.7% | 0.00% | 0.0% |
| Q3 2021 | $550,000 | -1.4% | 16,383 | +17.0% | 0.00% | 0.0% |
| Q2 2021 | $558,000 | -8.5% | 14,008 | +3.1% | 0.00% | 0.0% |
| Q1 2021 | $610,000 | +329.6% | 13,586 | +439.6% | 0.00% | – |
| Q4 2020 | $142,000 | +86.8% | 2,518 | +55.9% | 0.00% | – |
| Q3 2020 | $76,000 | -5.0% | 1,615 | +18.6% | 0.00% | – |
| Q2 2020 | $80,000 | -25.2% | 1,362 | -40.2% | 0.00% | – |
| Q1 2020 | $107,000 | -10.8% | 2,279 | +14.8% | 0.00% | – |
| Q4 2019 | $120,000 | -17.2% | 1,985 | -17.7% | 0.00% | – |
| Q3 2019 | $145,000 | +12.4% | 2,413 | +20.8% | 0.00% | – |
| Q2 2019 | $129,000 | -21.3% | 1,998 | -1.3% | 0.00% | – |
| Q1 2019 | $164,000 | +80.2% | 2,024 | +20.5% | 0.00% | – |
| Q4 2018 | $91,000 | -51.1% | 1,679 | -53.6% | 0.00% | -100.0% |
| Q3 2018 | $186,000 | -11.4% | 3,615 | -28.0% | 0.00% | 0.0% |
| Q2 2018 | $210,000 | -18.3% | 5,021 | -13.7% | 0.00% | 0.0% |
| Q1 2018 | $257,000 | -6.2% | 5,815 | +6.5% | 0.00% | 0.0% |
| Q4 2017 | $274,000 | +5.0% | 5,460 | +6.0% | 0.00% | 0.0% |
| Q3 2017 | $261,000 | -0.4% | 5,152 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $262,000 | +26.6% | 5,152 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $207,000 | -17.5% | 5,152 | -2.2% | 0.00% | 0.0% |
| Q4 2016 | $251,000 | +34.2% | 5,267 | +3.5% | 0.00% | 0.0% |
| Q3 2016 | $187,000 | +34.5% | 5,091 | -14.5% | 0.00% | 0.0% |
| Q2 2016 | $139,000 | -20.6% | 5,952 | +37.8% | 0.00% | 0.0% |
| Q1 2016 | $175,000 | -38.6% | 4,318 | -6.1% | 0.00% | 0.0% |
| Q4 2015 | $285,000 | – | 4,598 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |